Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Leading drugmaker Amgen could ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis The IGNITE study, which evaluated two dose strengths of ...

The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...